Birchview Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Birchview Capital’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50,000	Closed	-$518K	–	64
2022 Q1	$566K	Sell	50,000 -10,000	-17%	-$131K	0.41%	40
2021 Q4	$941K	Sell	60,000 -20,000	-25%	-$349K	0.61%	31
2021 Q3	$1.37M	Hold	80,000	–	–	0.93%	21
2021 Q2	$1.72M	Hold	80,000	–	–	1.03%	16
2021 Q1	$1.2M	Hold	80,000	–	–	0.71%	23
2020 Q4	$1.05M	Hold	80,000	–	–	0.61%	28
2020 Q3	$773K	Hold	80,000	–	–	0.52%	26
2020 Q2	$915K	Hold	80,000	–	–	0.55%	26
2020 Q1	$829K	Hold	80,000	–	–	0.74%	19
2019 Q4	$1.31M	Hold	80,000	–	–	0.95%	14
2019 Q3	$1.06M	Hold	80,000	–	–	0.71%	12
2019 Q2	$1.13M	Hold	80,000	–	–	0.69%	18
2019 Q1	$1.47M	Hold	80,000	–	–	0.92%	9
2018 Q4	$2.09M	Sell	80,000 -8,000	-9%	-$188K	1.98%	8
2018 Q3	$2.02M	Hold	88,000	–	–	1.3%	5
2018 Q2	$1.68M	Hold	88,000	–	–	1.14%	11
2018 Q1	$1.48M	Hold	88,000	–	–	0.98%	10
2017 Q4	$1.34M	Buy	88,000 +20,000	+29%	+$297K	0.78%	11
2017 Q3	$1.22M	Hold	68,000	–	–	0.63%	12
2017 Q2	$1.11M	Buy	68,000 +14,000	+26%	+$202K	0.59%	10
2017 Q1	$756K	Buy	54,000 +32,000	+145%	+$456K	0.42%	18
2016 Q4	$351K	Buy	+22,000	New	+$354K	0.22%	24

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Birchview Capital's VNDA Position: Q2 2022 in Review

Birchview Capital sold out of Vanda Pharmaceuticals (VNDA) in Q2 2022, closing a stake of 50,000 shares — an estimated $518K sold.

Birchview Capital first reported a position in VNDA in Q4 2016 and held it in 22 quarters. The position peaked at $2.09M in Q4 2018. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2022.

Birchview Capital reported no remaining Vanda Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Birchview Capital sold 50,000 Vanda Pharmaceuticals shares in Q2 2022, an estimated $518K.
Birchview Capital first reported a position in Vanda Pharmaceuticals in Q4 2016 and held it in 22 quarters.
Birchview Capital's Vanda Pharmaceuticals position peaked at $2.09M in Q4 2018.
173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2022.

Based on Birchview Capital's 13F filing for Q2 2022, filed 12 Aug 2022.